YOLFTbeta
Medigen Vaccine Biologics

Medigen Vaccine Biologics

6547 · TWO · Healthcare / Biotechnology

46.85TWD+0.05 (+0.11%)

Price History

Full chart

Market Stats

Previous Close46.80
Open46.70
Day Range46.55 – 48.10
52-Week Range33.50 – 72.20
Volume1.84M
Market Cap19.99B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.51
Dividend Yield0.00%
Beta0.00
50-Day Avg56.60
200-Day Avg47.09

About

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company has a collaboration with Charles River Laboratories for the development of next-generation multivalent enterovirus vaccines, enhance global regulatory readiness, and support IND-enabling non-clinical studies. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOLeo Lee
  • Employees0
  • HeadquartersNo. 68, Shengyi 3rd Road, Zhubei, Taiwan, 30261, Taiwan
  • Websitehttps://www.medigenvac.com

Leadership

  • Ms. Yu-Ping YangChief Financial Officer, Accounting Supervisor & Vice President of Administration Division
  • Mr. Cheng-Yang ChenHead of Project Management Department
  • Mr. He-Ru HsiehHead of Production Dept
  • Leo LeeChief Executive Officer & Executive VP
  • Mr. Szu-hsien LeePresident
  • Mr. Jia-En LiangDeputy General Manager of International & Public Affairs
  • Mr. Shih-Shen LeeExecutive Vice President of Operations Business Unit
  • Mr. Qing-An WuHead of Regulatory Affairs Dept.
  • Huai-En GanDeputy Head of Department
  • Shin-Yi FengHead of Audit

Financials

Income Statement

Currency: TWD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-------1.12M11.51M3.28B365.04M389.62M605.64M613.17M
Growth (%)--------+927.41%+28413.03%-88.87%+6.73%+55.44%+1.24%
Cost of Revenue---12.80M19.18M82.81M101.02M-3.87M975.96M577.64M168.48M209.22M248.50M
Gross Profit----12.80M-19.18M-82.81M-101.02M1.12M7.64M2.31B-212.60M221.15M396.42M364.67M
Gross Margin-------100.00%66.36%70.25%-58.24%56.76%65.46%59.47%
Operating Expense---170.43M200.40M253.23M365.31M599.71M665.50M888.76M1.24B1.43B542.09M630.37M
Operating Income-22.00M-76.71M-108.35M-183.23M-219.58M-336.04M-466.34M-598.59M-657.86M1.42B-1.45B-1.21B-145.67M-265.69M
Operating Margin--------53445.71%-5717.05%43.17%-396.58%-311.54%-24.05%-43.33%
EBITDA-20.72M-67.52M-93.78M-168.32M-188.31M-250.64M-365.00M-480.11M-535.61M1.53B-1.32B-1.08B74.86M-131.13M
EBITDA Margin--------42866.88%-4654.62%46.60%-361.55%-277.87%12.36%-21.38%
Net Income-22.00M-76.80M-105.41M-181.73M-209.58M-340.29M-476.34M-636.84M-690.70M1.41B-1.50B-1.16B-80.47M-281.71M
Net Income Margin--------56861.07%-6002.42%42.98%-411.31%-297.68%-13.29%-45.94%
R&D21.84M75.25M88.42M157.15M177.18M287.20M396.98M538.73M679.56M1.19B1.14B1.19B221.51M338.57M
R&D as % of Total Revenue-------48101.07%5905.59%36.36%312.29%306.04%36.58%55.22%
Interest Expense---606.00K2.10M6.83M10.32M19.13M16.42M6.02M26.89M37.57M18.89M8.80M
Interest Expense % of Total Revenue-------1707.68%142.69%0.18%7.37%9.64%3.12%1.44%

Balance Sheet

Currency: TWD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets150.15M477.40M1.21B1.65B1.82B2.14B2.18B2.28B3.49B5.30B7.35B6.09B4.36B3.93B
Total Liabilities22.15M19.46M135.95M309.19M347.90M615.41M571.10M910.28M349.40M622.95M2.32B2.25B513.92M454.64M
Total Equity128.00M457.94M1.08B1.34B1.47B1.52B1.61B1.37B3.14B4.68B5.03B3.85B3.85B3.48B
Cash39.77M326.91M168.56M536.69M286.52M608.07M217.08M410.62M1.68B1.38B1.20B1.35B715.61M592.04M
Total Debt-2.91M85.14M245.68M311.08M570.45M523.90M830.31M188.38M187.58M1.96B1.97B--
Net Debt-39.77M-324.00M-83.42M-291.01M24.56M-37.62M306.82M419.69M-1.49B-1.19B752.31M621.54M--

Cash Flow

Currency: TWD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-5.47M-72.36M-513.98M216.26M-163.37M-217.03M-356.33M-462.65M-589.97M579.89M-1.10B-477.75M40.75M-49.09M
Investing Cash Flow------92.78M-535.99M381.46M-76.30M-930.69M-2.40B---
Financing Cash Flow150.00M404.00M790.70M617.65M385.00M631.36M501.33M274.86M1.94B51.18M3.32B1.01M--
Capital Expenditure104.76M35.35M434.61M457.15M464.41M88.96M35.89M117.38M105.30M134.97M140.34M40.95M34.98M51.78M
Free Cash Flow-110.23M-107.71M-948.59M-240.89M-627.78M-305.99M-392.22M-580.02M-695.27M444.92M-1.24B-518.71M5.77M-100.86M
FCF to OCF2014.51%148.86%184.56%-111.39%384.28%140.99%110.07%125.37%117.85%76.73%112.75%108.57%14.17%205.48%

Earnings

Report DateMar 5, 2021May 7, 2021Jul 30, 2021Nov 10, 2021Mar 1, 2022Nov 7, 2022Mar 8, 2023May 15, 2023Aug 14, 2023Nov 2, 2023Mar 8, 2024Mar 5, 2025May 15, 2025Aug 13, 2025Nov 13, 2025Mar 13, 2026May 14, 2026Aug 12, 2026
EPS Estimate-0.92-3.47-1.25----1.25-1.06-1.05-0.51-0.49-0.01-0.080.070.090.030.06
EPS Actual-0.64-0.50-0.572.133.33-0.95-2.19-0.65-0.96-0.16-1.77-0.06-0.06-0.30-0.07-0.42-0.090.07
Surprise30.43%85.59%54.40%----75.20%38.68%8.57%68.63%-261.22%-500.00%--475.00%-200.00%-566.67%-400.00%16.67%
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-market-Pre-marketAfter-hoursPre-marketPre-marketAfter-hours

Key Statistics & Ratios

Market Cap19.99B
Enterprise Value19.05B
Trailing P/E0.00
Forward P/E0.00
Price / Sales34.83
Price / Book5.62
EPS-0.51
Book Value10.82
Revenue (TTM)573.85M
Gross Profit (TTM)361.55M
EBITDA-57.84M
Profit Margin-29.06%
Operating Margin18.58%
Return on Equity-4.62%
Return on Assets-2.55%
Shares Outstanding328.75M
Shares Float257.52M
Beta0.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 3, 20221482.8058:1000